| Companies sponsors |
CSL Behring (garadacimab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
None |
| Professional groups |
British Society for Immunology |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Immunology and Allergy Nurses Group |
| Associated public health groups |
None |
| Comparator companies |
BioCryst Pharmaceuticals (berotralstat) (confidentiality agreement signed, participating) |
| |
CSL Behring (Berinert) (confidentiality agreement signed, participating) |
| |
Takeda (Cinryze, lanadelumab) (confidentiality agreement signed, participating) |
| |
Maxwellia (tranexamic acid) (confidentiality agreement not signed, not participating) |
| |
Mylan (tranexamic acid) (confidentiality agreement not signed, not participating) |
| |
Pharming Group N.V (Ruconest) (confidentiality agreement not signed, not participating) |
| |
Rivopharm (tranexamic acid) (confidentiality agreement not signed, not participating) |
| |
Sovereign Medical (tranexamic acid) (confidentiality agreement not signed, not participating) |
| |
Tillomed Laboratories (tranexamic acid) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Nonr |